Literature DB >> 26071854

The Role of Radiotherapy in Small Cell Lung Cancer: a Revisit.

Gregory M M Videtic1.   

Abstract

Small cell lung cancer is staged as either limited (potentially curable) or extensive (incurable), based on the extent of disease in the chest. Limited stage disease is treated with concurrent chemotherapy and thoracic radiotherapy followed by prophylactic cranial irradiation (PCI). The conventional approach to extensive disease is chemotherapy only, with radiotherapy reserved for site-specific palliation. Recent reports suggest increasing applications for radiotherapy. The administration of PCI to extensive stage patients demonstrating response to chemotherapy is now recommended due to local control and overall survival benefits. Likewise, the role of consolidation chest radiotherapy after chemotherapy for advanced disease patients has seen a resurgence of interest in light of a recent publication suggesting improved local benefits which may influence survival. Recent technical advances in radiotherapy such as stereotactic body treatment and intensity-modulated therapy may also provide new indications for radiation, to enhance delivery and minimize toxicities.

Entities:  

Mesh:

Year:  2015        PMID: 26071854     DOI: 10.1007/s11912-015-0458-9

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  23 in total

Review 1.  Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer.

Authors:  Daniel B Fried; David E Morris; Charles Poole; Julian G Rosenman; Jan S Halle; Frank C Detterbeck; Thomas A Hensing; Mark A Socinski
Journal:  J Clin Oncol       Date:  2004-12-01       Impact factor: 44.544

Review 2.  The role of stereotactic body radiotherapy in the management of non-small cell lung cancer: an emerging standard for the medically inoperable patient?

Authors:  Gregory M M Videtic; Kevin L Stephans
Journal:  Curr Oncol Rep       Date:  2010-07       Impact factor: 5.075

3.  Estimated risk of perihippocampal disease progression after hippocampal avoidance during whole-brain radiotherapy: safety profile for RTOG 0933.

Authors:  Vinai Gondi; Wolfgang A Tome; James Marsh; Aaron Struck; Amol Ghia; Julius V Turian; Søren M Bentzen; John S Kuo; Deepak Khuntia; Minesh P Mehta
Journal:  Radiother Oncol       Date:  2010-04-12       Impact factor: 6.280

Review 4.  The role of radiation therapy in small cell lung cancer.

Authors:  Gregory M M Videtic
Journal:  Curr Oncol Rep       Date:  2013-08       Impact factor: 5.075

5.  Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01).

Authors:  C Le Péchoux; A Laplanche; C Faivre-Finn; T Ciuleanu; R Wanders; D Lerouge; R Keus; M Hatton; G M Videtic; S Senan; A Wolfson; R Jones; R Arriagada; E Quoix; A Dunant
Journal:  Ann Oncol       Date:  2010-12-07       Impact factor: 32.976

6.  Stereotactic body radiotherapy with concurrent chemotherapy extends survival of patients with limited stage small cell lung cancer: a single-center prospective phase II study.

Authors:  Chongyi Li; Yanli Xiong; Zejun Zhou; Yu Peng; Huan Huang; Mingfang Xu; Houyi Kang; Bo Peng; Dong Wang; Xueqin Yang
Journal:  Med Oncol       Date:  2014-11-22       Impact factor: 3.064

7.  Randomized Phase II Study Comparing Prophylactic Cranial Irradiation Alone to Prophylactic Cranial Irradiation and Consolidative Extracranial Irradiation for Extensive-Disease Small Cell Lung Cancer (ED SCLC): NRG Oncology RTOG 0937.

Authors:  Elizabeth M Gore; Chen Hu; Alexander Y Sun; Daniel F Grimm; Suresh S Ramalingam; Neal E Dunlap; Kristin A Higgins; Maria Werner-Wasik; Aaron M Allen; Puneeth Iyengar; Gregory M M Videtic; Russell K Hales; Ronald C McGarry; James J Urbanic; Anthony T Pu; Candice A Johnstone; Volker W Stieber; Rebecca Paulus; Jeffrey D Bradley
Journal:  J Thorac Oncol       Date:  2017-06-23       Impact factor: 15.609

Review 8.  Should aggressive surgery ever be part of the management of small cell lung cancer?

Authors:  Thomas K Waddell; Frances A Shepherd
Journal:  Thorac Surg Clin       Date:  2004-05       Impact factor: 1.750

9.  Prophylactic cranial irradiation in extensive disease small-cell lung cancer: short-term health-related quality of life and patient reported symptoms: results of an international Phase III randomized controlled trial by the EORTC Radiation Oncology and Lung Cancer Groups.

Authors:  Berend J Slotman; Murielle E Mauer; Andrew Bottomley; Corinne Faivre-Finn; Gijs W P M Kramer; Elaine M Rankin; Michael Snee; Matthew Hatton; Pieter E Postmus; Laurence Collette; Suresh Senan
Journal:  J Clin Oncol       Date:  2008-12-01       Impact factor: 44.544

10.  Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial.

Authors:  Cécile Le Péchoux; Ariane Dunant; Suresh Senan; Aaron Wolfson; Elisabeth Quoix; Corinne Faivre-Finn; Tudor Ciuleanu; Rodrigo Arriagada; Richard Jones; Rinus Wanders; Delphine Lerouge; Agnès Laplanche
Journal:  Lancet Oncol       Date:  2009-04-20       Impact factor: 41.316

View more
  2 in total

1.  Prophylactic cranial irradiation in patients with small cell lung cancer in The Netherlands: A population-based study.

Authors:  Mathijs L Tomassen; Mieke J Aarts; Max Peters; Anne van Lindert; Dirk K M De Ruysscher; Joost J C Verhoeff; Peter S N van Rossum
Journal:  Clin Transl Radiat Oncol       Date:  2021-02-12

2.  A clinicopathologic analysis of microscopic extension in small cell lung cancer and lung adenocarcinoma: Determination of clinical target volume with precise radiotherapy.

Authors:  Liwei Gao; Xiuhong Wang; Xiongtao Yang; Runchuan Gu; Guangying Zhu; Xianshu Gao
Journal:  Thorac Cancer       Date:  2021-05-24       Impact factor: 3.500

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.